These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 15293062)
1. The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients. Yumuk PF; Aydin SZ; Dane F; Gumus M; Ekenel M; Aliustaoglu M; Karamanoglu A; Sengoz M; Turhal SN Int J Colorectal Dis; 2004 Nov; 19(6):609-10. PubMed ID: 15293062 [No Abstract] [Full Text] [Related]
2. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486 [TBL] [Abstract][Full Text] [Related]
3. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. Kramar A; Gourgou-Bourgade S; Ychou M J Clin Oncol; 2005 Jan; 23(3):650; author reply 650-1. PubMed ID: 15659517 [No Abstract] [Full Text] [Related]
5. [Irinotecan in the second-line therapy of metastatic colorectal carcinoma]. Petrasch S; Dörr T; Kemmeries G Z Gastroenterol; 1999 Jun; 37(6):575-7. PubMed ID: 10427662 [No Abstract] [Full Text] [Related]
6. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755 [TBL] [Abstract][Full Text] [Related]
7. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer]. Guan ZZ Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384 [No Abstract] [Full Text] [Related]
8. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Reina JJ; Aparicio J; Salvador J; Pica JM; Rueda A; Lorenzo A; de la Puente CG; Borrega P; Moreno-Nogueira JA Cancer Chemother Pharmacol; 2003 Oct; 52(4):339-45. PubMed ID: 12851783 [TBL] [Abstract][Full Text] [Related]
9. [Relationship between UGT1A and irinotecan-related toxicity]. Xu JM Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):241-3. PubMed ID: 23985249 [No Abstract] [Full Text] [Related]
10. Irinotecan for metastatic colorectal cancer. Med Lett Drugs Ther; 1997 Jan; 39(992):8. PubMed ID: 9008684 [No Abstract] [Full Text] [Related]
11. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396 [TBL] [Abstract][Full Text] [Related]
12. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Schmittel A; Jahnke K; Thiel E; Keilholz U Ann Oncol; 2004 Aug; 15(8):1296. PubMed ID: 15277273 [No Abstract] [Full Text] [Related]
14. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Kee BK; Morris JS; Slack RS; Crocenzi T; Wong L; Esparaz B; Overman M; Glover K; Jones D; Wen S; Fisch MJ Support Care Cancer; 2015 Mar; 23(3):661-70. PubMed ID: 25160493 [TBL] [Abstract][Full Text] [Related]
15. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398 [TBL] [Abstract][Full Text] [Related]
17. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. Valencak J; Raderer M; Kornek GV; Henja MH; Scheithauer W J Natl Cancer Inst; 1998 Jan; 90(2):160. PubMed ID: 9450578 [No Abstract] [Full Text] [Related]
18. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. Michael M; Brittain M; Nagai J; Feld R; Hedley D; Oza A; Siu L; Moore MJ J Clin Oncol; 2004 Nov; 22(21):4410-7. PubMed ID: 15514383 [TBL] [Abstract][Full Text] [Related]